AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

RecruitingPhase 2Ages 18 Years - 75 YearsAllShanghai Yidian Pharmaceutical Technology Developโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for postoperative pain management in abdominal surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. 18 years old โ‰ค age โ‰ค 75 years old, gender is not limited. 2. 18 kg/m2 โ‰ค Body Mass Index (BMI) โ‰ค 30kg/m2. 3. Scheduled to undergo abdominal surgeries under general anesthesia. 4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers. Exclusion Criteria: 1. Prior history of surgery at the same site, and this may affect pain perception at the surgical site per investigator's judgments. 2. Allergy to any component of the investigational product, to perioperative anesthetic/analgesic/antiemetic agents, or to โ‰ฅ3 substance allergies. 3. Unstable angina, myocardial infarction, severe arrhythmias (e.g., third-degree atrioventricular block), New York Heart Association (NYHA) class III or higher cardiac function, recurrent asthma, etc., within screen period, and deemed ineligible per investigator's judgments. 4. High bleeding risk conditions: Congenital bleeding disorders (e.g., hemophilia), platelet function abnormalities (e.g., idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet function abnormalities), active bleeding, etc., and deemed ineligible per investigator's judgments. 5. For female participants: Pregnant or lactating (within 1 year postpartum). 6. Participants with childbearing potential planning conception/sperm/egg donation within 6 months post-treatment, or unwilling to use effective contraception (abstinence, barrier methods, oral contraceptives, intrauterine device, or sterilization). 7. Judgment by the investigator that the participant should not enter the study due to other conditions.
๐Ÿ’Š

What it tests

  • HL-1186
  • HL-1186 placebo
๐Ÿ“

Where

1 site
The Third Xiangya Hospital of Central South University
Changsha, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy